#USA #St. Louis #Joe McCann #TAG1 #Lead-212

Joe McCann Joins TAG1 Inc. Board of Directors

TAG1 Inc., a leading provider of medical isotopes, recently announced the appointment of Joe McCann to its Board of Directors. This significant move aims to enhance the company's capability to supply clinical quantities of isotopes, which are crucial for radiopharmaceutical applications. McCann, previously the CEO of POINT Biopharma, holds extensive experience in the pharmaceutical industry, particularly in radiopharmaceutical manufacturing and supply chain management.

An Industry Veteran

With decades of experience under his belt, McCann has successfully guided several companies through growth phases, clinical developments, and acquisitions. His expertise in operational strategy makes him a perfect fit for TAG1 as they aim to revolutionize the availability of radiopharmaceuticals. McCann's insight into the radiopharmaceutical landscape comes at a vital time when the demand for advanced medical treatments is on the rise, particularly for cancer therapies.

In his new role, McCann expressed his commitment to improving patient outcomes. He stated, "What drew me to radiopharma was how close the work is to the patient; you feel the impact of every decision. Whether it’s a manufacturing delay or a supply chain failure, there are real people affected on the other end. TAG1 understands this deeply, and I am excited to be part of a team focused on transforming access to essential isotopes."

Strengthening Supply Chain

A key focus for TAG1, with McCann on board, is to enhance the supply of Lead-212, an isotope critical for targeted alpha therapies (TATs). The development and accessibility of Lead-212 face several hurdles, primarily related to supply chain and infrastructure challenges. McCann’s leadership is expected to play a pivotal role in addressing these challenges, especially through the scaling of TAG1’s proprietary generator technology.

According to Sumit Verma, CEO and Founder of TAG1, "Joe understands the technical rigor and precision necessary for success in radiopharma. His history in building high-performing teams is a tremendous asset as we establish a reliable, patient-focused supply chain for Lead-212.” This sentiment underlines the importance of McCann’s contribution to the board, which aims to ensure a steady and effective supply of isotopes critical for medical advancements.

A Decentralized Approach

TAG1's proprietary generator is designed to decentralize the production of Lead-212, providing consistent access to hospitals, radiopharmacies, and research institutions. This innovative approach not only ensures that isotopes are available when needed but also enhances the efficiency of distribution, ultimately benefitting patients who rely on these advanced therapies.

Dimitrios Mantzilas, CTO of Precirix and TAG1 Board Member, also welcomed McCann, stating, "We’re excited to welcome such a visionary leader to TAG1's Board. Joe’s understanding of the industry is second to none, and his clarity of purpose is urgently needed in our field, particularly as alpha therapies gain momentum. His experience will be invaluable as we shift from development into sustained delivery.”

Looking Ahead

As TAG1 Inc. continues to grow and innovate, the addition of Joe McCann to its Board of Directors not only strengthens the company’s operational foundation but also reinforces its commitment to improving cancer treatment and patient care. McCann’s involvement exemplifies a critical step toward advancing the radiopharmaceutical supply chain, which holds the potential to transform the landscape of cancer therapies through groundbreaking innovations in nuclear medicine.

With TAG1’s mission to enhance patient outcomes through innovative production of medical isotopes, the future looks promising for advancements in radiopharmaceuticals, boosting both the technology and accessibility of crucial treatments for patients worldwide.